medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2018, Número 2

Rev Invest Clin 2018; 70 (2)


Pulmonary Vasoreactivity and Phenotypes in Pulmonary Arterial Hypertension Associated to Connective Tissue Diseases

Hernández-Oropeza JL, Rodríguez-Reyna TS, Carrillo-Pérez DL, Rodríguez-Andoney JJ, Narváez-David R, Salado-Morales Y, Rivero-Sigarroa E, Domínguez-Cherit G, Pulido-Zamudio T

Idioma: Inglés
Referencias bibliográficas: 13
Paginas: 82-87
Archivo PDF: 75.16 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Heart J. 2016;37:67-119.

  2. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62:D42-50.

  3. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138:1383-94.

  4. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium- channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.

  5. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-11.

  6. Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31:1898-907.

  7. Halliday SJ, Hemnes AR, Robbins IM, et al. Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the “classic” responders. J Heart Lung Transplant. 2015; 34:312-8.

  8. Malhotra R, Hess D, Lewis GD, Bloch KD, Waxman AB, Semigran MJ. Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension. Pulm Circ. 2011;1:250-8.

  9. Jing ZC, Jiang X, Han ZY, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J. 2009;33:1354-60.

  10. Badesch DB, Raskob GE, Elliot CG, et al. Pulmonary arterial hypertension. Baseline characteristics from the REVEAL Registry. Chest. 2010;137:376-87.

  11. Skoro-Sajer N, Hack N, Sadushi-Koliçi R, et al. Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot study. Circulation. 2009; 119:298-305.

  12. Sobansky V, Giovannelli J, Lynch BM, et al. Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol. 2016;68:484-93.

  13. Huang C, Li M, Liu Y, Wang Q, Guo X, Zhao J. Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients. Medicine. 2016;95:1-7.




2020     |     www.medigraphic.com